Zilovertamab vedotin - VelosBio
Alternative Names: MK 2140; VLS 101Latest Information Update: 07 Jan 2025
Price :
$50 *
At a glance
- Originator Merck Sharp & Dohme; VelosBio
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Diffuse large B cell lymphoma
- Phase II Bladder cancer; Breast cancer; Chronic lymphocytic leukaemia; Follicular lymphoma; Gastric cancer; Haematological malignancies; Mantle-cell lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Richter's syndrome; Solid tumours
- Preclinical Ewing's sarcoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 27 Dec 2024 Phase-III clinical trials in Diffuse large B cell lymphoma (First-line therapy, Combination therapy) in USA (IV) (NCT06717347)
- 09 Dec 2024 Interim adverse events data from a phase II trial in Diffuse large B cell lymphoma released by Merck
- 08 Dec 2024 Merck Sharp & Dohme plans a phase III waveLINE-010 trial in Diffuse large B cell lymphoma (Combination therapy, First-line therapy) in December 2024 (IV, Infusion) (NCT06717347)